Filing Details

Accession Number:
0001447362-21-000148
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-17 17:36:25
Reporting Period:
2021-06-15
Accepted Time:
2021-06-17 17:36:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1447362 Castle Biosciences Inc CSTL Services-Medical Laboratories (8071) 770701774
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1782815 Frank Stokes C/O Castle Biosciences, Inc.
505 S. Friendswood Drive, Suite 401
Friendswood TX 77546
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-06-15 11,600 $2.39 17,520 No 4 M Direct
Common Stock Disposition 2021-06-15 11,600 $73.02 5,920 No 4 S Direct
Common Stock Acquisiton 2021-06-16 2,127 $2.39 8,047 No 4 M Direct
Common Stock Disposition 2021-06-16 2,127 $73.07 5,920 No 4 S Direct
Common Stock Acquisiton 2021-06-17 1,273 $2.39 7,193 No 4 M Direct
Common Stock Disposition 2021-06-17 1,273 $73.00 5,920 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2021-06-15 11,600 $0.00 11,600 $2.39
Common Stock Stock option (right to buy) Disposition 2021-06-16 2,127 $0.00 2,127 $2.39
Common Stock Stock option (right to buy) Disposition 2021-06-17 1,273 $0.00 1,273 $2.39
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
28,537 2028-05-09 No 4 M Direct
26,410 2028-05-09 No 4 M Direct
25,137 2028-05-09 No 4 M Direct
Footnotes
  1. These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 14, 2021.
  2. Includes 2,034 shares acquired on February 26, 2021 under the Issuer's employee stock purchase plan.
  3. This transaction was executed in multiple trades at prices ranging from $73.00 to $73.13, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. This transaction was executed in multiple trades at prices ranging from $73.00 to $73.33, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.